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Abstract: Azole resistance in Aspergillus fumigatus is an emerging public health concern. 21 
Recently, a novel fungicide-driven mutation in the cyp51A gene and its promoter, 22 
TR46/Y121F/T289A, leading to high-level resistance to voriconazole has been identified in 23 
the Netherlands, Belgium, Germany, Denmark, Tanzania and India in both clinical and 24 
environmental samples. Here we report the first description of A. fumigatus carrying this 25 
mutation in France, in a cystic fibrosis patient, underlining the need for extensive monitoring 26 
of Aspergillus resistance. 27 
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Azole-resistant Aspergillus fumigatus are increasingly reported in Europe since the late 2000s. 28 
This emerging public health concern occurs through two distinct routes of acquisition: in vivo 29 
selection of resistance as a consequence of long-term azole treatment or de novo acquisition 30 
of a resistant isolate directly from the environment, linked to the widespread use of azole 31 
fungicides in agriculture. Besides the TR34/L98H mutation in the cyp51A gene first described 32 
in the Netherlands, a novel fungicide-driven mutation, TR46/Y121F/T289A has been recently 33 
identified. Up to now, the TR46/Y121F/T289A mutation has been reported in both 34 
environmental and/or clinical samples in four countries across Europe (1-7), in Asia (8) and 35 
more recently in Africa (9), suggesting a large geographical spread. Here we provide the first 36 
description of A. fumigatus carrying TR46/Y121F/T289A mutation in France, in a cystic 37 
fibrosis patient. 38 
 39 
A 23-year-old male cystic fibrosis patient with follow-up at the Pneumology Department at 40 
Rouen University Hospital, France, was seen in consultation in March 2014. This patient had 41 
high levels of total IgE and Aspergillus-specific IgE with positive Aspergillus-specific IgG 42 
antibodies, being suggestive of diagnosis of allergic bronchopulmonary aspergillosis. He had 43 
a history of A. fumigatus airway colonization and mold-active azoles exposure since 2002 44 
(itraconazole and voriconazole). At the time of the consultation, he was treated with 45 
voriconazole. Mycological cultures of the sputum collected during the consultation grew A. 46 
fumigatus (strain 1). Species identification was obtained by both macroscopic and 47 
microscopic characteristics on Sabouraud’s agar medium together with sequencing of the 48 
beta-tubulin gene (10). According to a local research protocol aiming at the surveillance of 49 
azole resistance, this isolate was tested for antifungal susceptibility by the Etest® method 50 
(bioMérieux, Marcy-l’Etoile, France). Unexpectedly, this strain exhibited a high-level 51 
resistance to voriconazole (MIC>32µg/mL) in contrast with itraconazole (MIC=8µg/mL) and 52 
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posaconazole (MIC=1µg/mL). Antifungal susceptibility was confirmed by the EUCAST broth 53 
microdilution reference method (Table 1) (11, 12). Nucleotide sequencing of the cyp51A gene 54 
and its promoter, using previously described primers (13, 14) and home-designed primers 55 
(CYP51AF-F1: 5’-ATTTCCCTCATCACTGCAA, CYP51AF-R1: 5’-56 
CATCATGTGCGCAATCTCTT, CYP51AF-F2: 5’-AGAAGCGAGATGCTGCTCAT, 57 
CYP51AF-R2: 5’-CCTTTGAAGTCCTCGATGGT), showed the TR46/Y121F/T289A 58 
mutation. Antifungal therapy was therefore switched to posaconazole in April 2014 then to 59 
caspofungin (50 mg per day) in July 2014 because of pulmonary exacerbation. 60 
Given these findings, we retrospectively analyzed all A. fumigatus strains previously isolated 61 
from this patient since 2007 (n=13), for itraconazole and voriconazole susceptibility, cyp51A 62 
sequencing and microsatellite genotyping. As shown in Table 1, our patient had already been 63 
colonized by a TR46/Y121F/T289A isolate one year before, in February 2013 (strain 3). All 64 
remaining isolates collected before February 2013 were azole-susceptible being either wild-65 
type for the cyp51A gene or carrying mutations previously found in both azole-resistant and 66 
azole-susceptible isolates (15). As a single colony was subjected to in vitro susceptibility 67 
testing other azole-resistant isolates could have been missed. Microsatellite genotyping was 68 
performed using a panel of nine short tandem repeats as described previously (16). As 69 
illustrated in Table 1, both TR46/Y121F/T289A isolates from our patient had the same 70 
genotype as a strain previously isolated in Germany (7) (Table 1). To gain further insights into 71 
the route of acquisition of this azole-resistant isolate in our patient, we conducted an 72 
environmental study by soil samplings next to the patient’s home as described previously 73 
(17), as well as surface samplings (contact agar plates) in his office. Neither A. fumigatus 74 
carrying TR46/Y121F/T289A nor TR34/L98H was identified. 75 
 76 
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Aspergillus fumigatus isolates carrying the TR46/Y121F/T289A mutation have been first 77 
described in December 2009 in the Netherlands (2). Since then, such isolates have been 78 
evidenced in three others European countries namely Belgium (1, 5), Germany (3, 7) and 79 
Denmark (4) and recently in India (8) and Tanzania (9) (Table 2, Figure 1). Taken together, 80 
these findings suggest, as discussed previously for TR34/L98H isolates, a large geographical 81 
spread of this resistance mechanism. Several lines of evidence indicate that, as for 82 
TR34/L98H, TR46/Y121F/T289A has emerged through a fungicide-driven route (18), such 83 
isolates being found in both azole-naïve (1, 2, 6, 7) and azole-exposed patients (2, 3, 5, 7) as 84 
well as from the environment (2, 8, 9). Here we report the first description of A. fumigatus 85 
carrying the TR46/Y121F/T289A mutation isolated from a French patient.  86 
Interestingly, our patient organized trips to the Netherlands as a tour operator. For these 87 
working purposes, he traveled to Amsterdam in November 2012, three months before the first 88 
isolation of the TR46/Y121F/T289A strain from his sputum (February 2013). Moreover he 89 
regularly received advertising postal packages from Dutch flower producers which were 90 
opened in his office. Three hypotheses can explain the route of acquisition of this 91 
TR46/Y121F/T289A strain in our patient: (i) inhalation of spores carrying TR46/Y121F/T289A 92 
during his trip to the Netherlands (2); (ii) colonization after inhaling spores carrying 93 
TR46/Y121F/T289A from his environment in France. Our environmental study conducted 94 
next to the patient’s home, less than 100 km from Belgium (where TR46/Y121F/T289A strains 95 
have been recently identified (1)), failed to detect TR46/Y121F/T289A environmental isolates. 96 
Nevertheless, environmental isolates carrying this mutation have been recently identified by 97 
our team in the same region in France supporting this hypothesis (unpublished data). (iii) The 98 
last hypothesis is colonization after inhaling A. fumigatus spores carrying 99 
TR46/Y121F/T289A, escaping while opening the packages received from the Netherlands. 100 
Though the French strains are genetically indistinguishable from the German and genetically 101 
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different from Dutch isolates, the route of acquisition in our patient is unclear, as spores 102 
probably follow an airborne migration as hypothesized previously for TR34/L98H (19, 20). 103 
The present report now provides evidence that A. fumigatus voriconazole-resistant isolates 104 
carrying the TR46/Y121F/T289A mutation can be now isolated from clinical samples in 105 
France. As observed with TR34/L98H, a geographical spread of this resistance mechanism is 106 
ongoing across Europe and possibly worldwide. These findings together with the high-level 107 
voriconazole resistance of the TR46/Y121F/T289A strains both in vitro and in vivo (1, 2, 4-6) 108 
underline the need for intensive investigations to determine its prevalence in both clinical and 109 
environmental samples. In line with this, as recommended by the ECDC Technical report 110 
(18), antifungal susceptibility testing of triazoles should be performed on all clinical A. 111 
fumigatus isolates before starting antifungal therapy. 112 
 113 
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Table 1- Overview of the characteristics of all Aspergillus fumigatus strains isolated from 
sputum samples of the patient 
Strain 
number 
Reference in the 
dendrogram 
Month/Year 
of isolation 
MICs mg/L 
(EUCAST) 
Cyp51A mutations 
ITC VRC 
1 14-105-2468 Mar 2014 8 >8 TR46/Y121F/T289A 
2 14-148-2457 Nov 2013 0.5 0.5 Wild-type 
3 14-148-2460 Feb 2013 >8 >8 TR46/Y121F/T289A 
4 141428-459 Jan 2013 0.5 1 Wild-type 
5 14-148-2458 Jan 2013 0.25 0.25 Wild-type 
6 14-148-2456 Dec 2010 Not performed F46Y, G89G, M172V, N248T, D255E, L358L, E427K, C454C 
7 14-148-2455 Sept 2010 Not performed F46Y, G89G, M172V, N248T, D255E, L358L, E427K, C454C 
8 14-148-2454 Jul 2010 Not performed F46Y, G89G, M172V, N248T, D255E, L358L, E427K, C454C 
9 Not performed Jul 2009 Not performed F46Y, G89G, M172V, N248T, D255E, L358L, E427K, C454C 
10 14-148-2450 Jul 2009 0.25 1 Wild-type 
11 14-148-2448 Mar 2009 0.25 1 Wild-type 
12 14-148-2447 Dec 2007 0.25 1 Wild-type 
13 14-148-2445 May 2007 0.5 2 Wild-type 
14 Not performed Feb 2007 0.5 1 F46Y, G89G, M172V, N248T, D255E, L358L, E427K, C454C 
 
Table 2- Literature review of all studies reporting TR46/Y121F/T289A A. fumigatus isolates 
Reference Date Type of sample Underlying condition Infection Antifungal susceptibility 
CLSI (EUCAST*) 
Outcome Country 
VRC ITC POS 
(1) July 2012 BAL fluid HSCT Probable IA >16 4 1 Death Belgium 
(2) 
Dec 2009 Sputum HSCT Probable IA >16 4 0.25 Persistent infection 
The Netherlands 
Jan 2010 Ear Chronic otitis externals/sinusitis IA >16 >16 2 Persistent infection 
Jan 2010 Abdominal abscess SOT Proven IA >16 2 0.5 Death 
Feb 2010 Sputum Cystic fibrosis No IA >16 4 0.5 Alive 
Feb 2010 Sputum Lung carcinoma No IA >16 >16 2 Alive 
March 2010 Sputum HSCT Probable IA >16 1 0.25 Death 
March 2010 Sputum Cystic fibrosis, SOT Proven IA >16 >16 0.5 Alive 
May 2010 Biopsy Chronic otitis, surgery Proven IA >16 4 1 Alive 
May 2010 Sputum Lung fibrosis None >16 >16 1 Alive 
June 2010 Sputum Traumatism None >16 1 0.25 Death 
July 2010 Brain biopsy Beta thalassemia, diabetes mellitus Proven IA >16 4 1 Death 
Sept 2010 Sputum Cystic fibrosis ABPA >16 2 0.5 Alive 
Oct 2010 Sputum COPD, SOT None >16 >16 2 Alive 
Nov 2010 Sputum COPD No IA >16 >16 2 Alive 
Jan 2011 Sputum HSCT Probable IA >16 >16 1 Death 
Dec 2009  
to Jan 2011 Air sampling   ND ND ND  
(8) 2012-2013 Soil sampling   >16 1-2 0.25-0.5  India 
(3) Sept 2012 Sputum Cystic fibrosis Colonization >8* >8* 2* Alive Germany 
(4) Jan 2014 Sputum Bruton’s agammaglobulinemia, SOT Probable IA >4* 0.25-0.5* 
0.125-
0.25* Death Denmark 
(9)  Soil sampling   16->16 1-2 0.25-0.5  Tanzania 
(5) Nov 2013 BAL fluid HSCT Probable IA >8 >16 1 Death Belgium 
(7) Sept 2012 BAL fluid HSCT Probable IA 16* >16* 0.5* Death Germany July 2012 BAL fluid HSCT Proven IA 1* >16* 0.5* Death 
Present report Feb 2013 March 2014 Sputum Cystic fibrosis Colonization 
>8* 
>8* 
>8* 
8* ND Alive France 
POS: posaconazole 
BAL: bronchoalveolar lavage; HSCT: hematopoietic stem cell transplantation; IA: invasive aspergillosis; SOT: solid organ transplantation; ABPA: allergic bronchopulmonary aspergillosis; 
COPD: chronic obstructive pulmonary disease; ND: Not determined 


